AMGN vs MRK
AMGN: A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures. MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda.
Side-by-side fundamentals
| Metric | AMGN | MRK | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $363.62 | $125.07 | |
| Market cap as of 2026-07-10 | $198.6B | $310.1B | |
| P/E as of 2026-07-10 | 25.46 | 34.71 | AMGN lower |
| PEG as of 2026-07-10 | 4.93 | 4.34 | MRK lower |
| Net margin as of 2026-07-10 | +21.0% | +13.6% | AMGN higher |
| Gross margin as of 2026-07-10 | +74.0% | +78.1% | MRK higher |
| Operating margin as of 2026-07-10 | +28.8% | +18.2% | AMGN higher |
| ROE as of 2026-07-10 | +89.4% | +17.9% | AMGN higher |
| ROA as of 2026-07-10 | +8.6% | +7.0% | AMGN higher |
| Debt / equity as of 2026-07-10 | 6.24 | 1.07 | MRK lower |
| Revenue growth (YoY) as of 2026-07-10 | +9.1% | +2.9% | AMGN higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +3.1% | AMGN higher |
| Dividend yield as of 2026-07-10 | +2.7% | +2.7% | AMGN higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-10 | 0.43 | 0.21 | |
| 1-year return as of 2026-07-09 close | +22.6% | +49.4% | MRK higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.